$3.77
+0.20 (+5.60%)
Open$3.54
Previous Close$3.57
Day High$3.86
Day Low$3.54
52W High$53.59
52W Low$32.71
Volume—
Avg Volume461.3K
Market Cap238.57M
P/E Ratio—
EPS$0.21
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+1,203.4% upside
Current
$3.77
$3.77
Target
$49.14
$49.14
$35.75
$49.14 avg
$66.29
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 30.91M | 31.76M | 28.92M |
| Net Income | 1.41M | 1.18M | 1.33M |
| Profit Margin | 4.6% | 3.7% | 4.6% |
| EBITDA | 2.44M | 2.48M | 2.21M |
| Free Cash Flow | 625.5K | 903.7K | 487.2K |
| Rev Growth | +22.5% | -3.0% | +24.7% |
| Debt/Equity | 0.57 | 0.48 | 0.69 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |